182 related articles for article (PubMed ID: 37647991)
1. Molecular-based targeted therapies in patients with hepatocellular carcinoma and hepato-cholangiocarcinoma refractory to atezolizumab/bevacizumab.
Limousin W; Laurent-Puig P; Ziol M; Ganne-Carrié N; Nahon P; Ait-Omar A; Seror O; Sidali S; Campani C; Blanc P; Lermine A; Marisa L; Zucman-Rossi J; Nault JC
J Hepatol; 2023 Dec; 79(6):1450-1458. PubMed ID: 37647991
[TBL] [Abstract][Full Text] [Related]
2. Atezolizumab and bevacizumab for non-resectable or metastatic combined hepatocellular-cholangiocarcinoma: A multicentric retrospective study.
Gigante E; Bouattour M; Bedoya JU; Regnault H; Ziol M; Assenat E; Paradis V; Calderaro J; Ganne-Carrié N; Bouhier-Leporrier K; Amaddeo G; Nault JC
United European Gastroenterol J; 2024 May; 12(4):429-439. PubMed ID: 38059651
[TBL] [Abstract][Full Text] [Related]
3. Artificial intelligence-based pathology as a biomarker of sensitivity to atezolizumab-bevacizumab in patients with hepatocellular carcinoma: a multicentre retrospective study.
Zeng Q; Klein C; Caruso S; Maille P; Allende DS; Mínguez B; Iavarone M; Ningarhari M; Casadei-Gardini A; Pedica F; Rimini M; Perbellini R; Boulagnon-Rombi C; Heurgué A; Maggioni M; Rela M; Vij M; Baulande S; Legoix P; Lameiras S; ; Bruges L; Gnemmi V; Nault JC; Campani C; Rhee H; Park YN; Iñarrairaegui M; Garcia-Porrero G; Argemi J; Sangro B; D'Alessio A; Scheiner B; Pinato DJ; Pinter M; Paradis V; Beaufrère A; Peter S; Rimassa L; Di Tommaso L; Vogel A; Michalak S; Boursier J; Loménie N; Ziol M; Calderaro J
Lancet Oncol; 2023 Dec; 24(12):1411-1422. PubMed ID: 37951222
[TBL] [Abstract][Full Text] [Related]
4. Alterations in DNA Damage Repair Genes in Primary Liver Cancer.
Lin J; Shi J; Guo H; Yang X; Jiang Y; Long J; Bai Y; Wang D; Yang X; Wan X; Zhang L; Pan J; Hu K; Guan M; Huo L; Sang X; Wang K; Zhao H
Clin Cancer Res; 2019 Aug; 25(15):4701-4711. PubMed ID: 31068370
[TBL] [Abstract][Full Text] [Related]
5. Clinical outcomes of immune checkpoint inhibitors in unresectable or metastatic combined hepatocellular-cholangiocarcinoma.
Jang YJ; Kim EJ; Kim HD; Kim KP; Ryu MH; Park SR; Choi WM; Lee D; Choi J; Shim JH; Kim KM; Lim YS; Lee HC; Ryoo BY; Yoo C
J Cancer Res Clin Oncol; 2023 Aug; 149(10):7547-7555. PubMed ID: 36971796
[TBL] [Abstract][Full Text] [Related]
6. Genetics of hepatobiliary carcinogenesis.
Nault JC; Zucman-Rossi J
Semin Liver Dis; 2011 May; 31(2):173-87. PubMed ID: 21538283
[TBL] [Abstract][Full Text] [Related]
7. Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial.
Galle PR; Finn RS; Qin S; Ikeda M; Zhu AX; Kim TY; Kudo M; Breder V; Merle P; Kaseb A; Li D; Mulla S; Verret W; Xu DZ; Hernandez S; Ding B; Liu J; Huang C; Lim HY; Cheng AL; Ducreux M
Lancet Oncol; 2021 Jul; 22(7):991-1001. PubMed ID: 34051880
[TBL] [Abstract][Full Text] [Related]
8. Mutational spectrum and precision oncology for biliary tract carcinoma.
Lin J; Cao Y; Yang X; Li G; Shi Y; Wang D; Long J; Song Y; Mao J; Xie F; Bai Y; Zhang L; Yang X; Wan X; Wang A; Guan M; Zhao L; Hu K; Pan J; Huo L; Lu X; Mao Y; Sang X; Zhang H; Wang K; Wang X; Zhao H
Theranostics; 2021; 11(10):4585-4598. PubMed ID: 33754015
[No Abstract] [Full Text] [Related]
9. Molecular Profiling and Targeted Therapy in Cholangiocarcinoma: An Observational, Retrospective Multicenter Study.
Garcia-Pardo M; Ortega L; Fernández-Aceñero MJ; García Alfonso P; Martín M; Muñoz AJ
J Gastrointest Cancer; 2021 Jun; 52(2):814-818. PubMed ID: 33683644
[TBL] [Abstract][Full Text] [Related]
10. Mixed hepatocellular cholangiocarcinoma tumors: Cholangiolocellular carcinoma is a distinct molecular entity.
Moeini A; Sia D; Zhang Z; Camprecios G; Stueck A; Dong H; Montal R; Torrens L; Martinez-Quetglas I; Fiel MI; Hao K; Villanueva A; Thung SN; Schwartz ME; Llovet JM
J Hepatol; 2017 May; 66(5):952-961. PubMed ID: 28126467
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the interest to combine a CD4 Th1-inducer cancer vaccine derived from telomerase and atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: a randomized non-comparative phase II study (TERTIO - PRODIGE 82).
Vienot A; Jacquin M; Rebucci-Peixoto M; Pureur D; Ghiringhelli F; Assenat E; Hammel P; Rosmorduc O; Stouvenot M; Allaire M; Bouattour M; Regnault H; Fratte S; Raymond E; Soularue E; Husson-Wetzel S; Di Martino V; Muller A; Clairet AL; Fagnoni-Legat C; Adotevi O; Meurisse A; Vernerey D; Borg C
BMC Cancer; 2023 Jul; 23(1):710. PubMed ID: 37516867
[TBL] [Abstract][Full Text] [Related]
12. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study.
Lee MS; Ryoo BY; Hsu CH; Numata K; Stein S; Verret W; Hack SP; Spahn J; Liu B; Abdullah H; Wang Y; He AR; Lee KH;
Lancet Oncol; 2020 Jun; 21(6):808-820. PubMed ID: 32502443
[TBL] [Abstract][Full Text] [Related]
13. Protocol of the RACB study: a multicenter, single-arm, prospective study to evaluate the efficacy of resection of initially unresectable hepatocellular carcinoma with atezolizumab combined with bevacizumab.
Okuno M; Ishii T; Ichida A; Soyama A; Takemura N; Hirono S; Eguchi S; Hasegawa K; Sasaki Y; Uemura K; Kokudo N; Hatano E
BMC Cancer; 2023 Aug; 23(1):780. PubMed ID: 37605169
[TBL] [Abstract][Full Text] [Related]
14. Perfusion Change of Hepatocellular Carcinoma During Atezolizumab plus Bevacizumab Treatment: A Pilot Study.
Onuoha E; Smith AD; Cannon R; Khushman M; Kim H
J Gastrointest Cancer; 2023 Sep; 54(3):776-781. PubMed ID: 36030519
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma.
Su D; Wu B; Shi L
JAMA Netw Open; 2021 Feb; 4(2):e210037. PubMed ID: 33625508
[TBL] [Abstract][Full Text] [Related]
16. Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFITY score.
Scheiner B; Pomej K; Kirstein MM; Hucke F; Finkelmeier F; Waidmann O; Himmelsbach V; Schulze K; von Felden J; Fründt TW; Stadler M; Heinzl H; Shmanko K; Spahn S; Radu P; Siebenhüner AR; Mertens JC; Rahbari NN; Kütting F; Waldschmidt DT; Ebert MP; Teufel A; De Dosso S; Pinato DJ; Pressiani T; Meischl T; Balcar L; Müller C; Mandorfer M; Reiberger T; Trauner M; Personeni N; Rimassa L; Bitzer M; Trojan J; Weinmann A; Wege H; Dufour JF; Peck-Radosavljevic M; Vogel A; Pinter M
J Hepatol; 2022 Feb; 76(2):353-363. PubMed ID: 34648895
[TBL] [Abstract][Full Text] [Related]
17. Identification of novel therapeutic targets in the PI3K/AKT/mTOR pathway in hepatocellular carcinoma using targeted next generation sequencing.
Janku F; Kaseb AO; Tsimberidou AM; Wolff RA; Kurzrock R
Oncotarget; 2014 May; 5(10):3012-22. PubMed ID: 24931142
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of erlotinib and docetaxel in advanced and refractory hepatocellular and biliary cancers: Hoosier Oncology Group GI06-101.
Chiorean EG; Ramasubbaiah R; Yu M; Picus J; Bufill JA; Tong Y; Coleman N; Johnston EL; Currie C; Loehrer PJ
Oncologist; 2012; 17(1):13. PubMed ID: 22210086
[TBL] [Abstract][Full Text] [Related]
19. Advanced hepatocellular carcinoma with response to lenvatinib after atezolizumab plus bevacizumab.
Yano S; Kawaoka T; Johira Y; Miura R; Kosaka M; Shirane Y; Murakami S; Amioka K; Naruto K; Ando Y; Kosaka Y; Yamaoka K; Kodama K; Uchikawa S; Fujino H; Ohno A; Nakahara T; Murakami E; Okamoto W; Yamauchi M; Imamura M; Mori K; Arihiro K; Kuroda S; Kobayashi T; Ohdan H; Aikata H
Medicine (Baltimore); 2021 Oct; 100(42):e27576. PubMed ID: 34678902
[TBL] [Abstract][Full Text] [Related]
20. Genomic Profiling of Combined Hepatocellular Cholangiocarcinoma Reveals Genomics Similar to Either Hepatocellular Carcinoma or Cholangiocarcinoma.
Murugesan K; Sharaf R; Montesion M; Moore JA; Pao J; Pavlick DC; Frampton GM; Upadhyay VA; Alexander BM; Miller VA; Javle MM; Bekaii Saab TS; Albacker LA; Ross JS; Ali SM
JCO Precis Oncol; 2021 Aug; 5():. PubMed ID: 34476330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
